With Medicare now negotiating prices for some of the most widely used and expensive drugs in the U.S., the spotlight is on how these MFP drug selections will affect patients, manufacturers, providers, and the broader healthcare marketplace.

Chelsea and Logan break down what it means to be an “MFP drug,” how the negotiation process works, and what stakeholders should be watching as implementation continues.

If you work in healthcare policy, pharmacy, drug pricing, Medicare, or 340B compliance, this is a must-listen conversation on one of the biggest shifts in pharmaceutical reimbursement in decades.

👉 Subscribe for more weekly discussions on 340B, Medicare reform, drug pricing policy, and healthcare legislation.